HRP20171515T1 - Spojevi fenoksietilpiperidina - Google Patents

Spojevi fenoksietilpiperidina Download PDF

Info

Publication number
HRP20171515T1
HRP20171515T1 HRP20171515TT HRP20171515T HRP20171515T1 HR P20171515 T1 HRP20171515 T1 HR P20171515T1 HR P20171515T T HRP20171515T T HR P20171515TT HR P20171515 T HRP20171515 T HR P20171515T HR P20171515 T1 HRP20171515 T1 HR P20171515T1
Authority
HR
Croatia
Prior art keywords
pharmaceutically acceptable
compound
acceptable salt
image
intended
Prior art date
Application number
HRP20171515TT
Other languages
English (en)
Croatian (hr)
Inventor
Matthew Allen Schiffler
Jeremy Schulenburg York
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of HRP20171515T1 publication Critical patent/HRP20171515T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/45Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20171515TT 2012-06-29 2013-06-20 Spojevi fenoksietilpiperidina HRP20171515T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261665951P 2012-06-29 2012-06-29
US201361779099P 2013-03-13 2013-03-13
EP13734248.1A EP2867207B1 (en) 2012-06-29 2013-06-20 Phenoxyethyl piperidine compounds
PCT/US2013/046684 WO2014004229A1 (en) 2012-06-29 2013-06-20 Phenoxyethyl piperidine compounds

Publications (1)

Publication Number Publication Date
HRP20171515T1 true HRP20171515T1 (hr) 2017-11-17

Family

ID=48746666

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20171515TT HRP20171515T1 (hr) 2012-06-29 2013-06-20 Spojevi fenoksietilpiperidina

Country Status (42)

Country Link
US (2) US8962659B2 (enExample)
EP (1) EP2867207B1 (enExample)
JP (1) JP6127136B2 (enExample)
KR (1) KR101653476B1 (enExample)
CN (1) CN104411684B (enExample)
AP (1) AP2014008164A0 (enExample)
AR (1) AR091429A1 (enExample)
AU (1) AU2013280875B2 (enExample)
BR (1) BR112014031616B1 (enExample)
CA (1) CA2875569C (enExample)
CL (1) CL2014003535A1 (enExample)
CO (1) CO7151507A2 (enExample)
CR (1) CR20140553A (enExample)
CY (1) CY1119425T1 (enExample)
DK (1) DK2867207T3 (enExample)
DO (1) DOP2014000287A (enExample)
EA (1) EA024392B1 (enExample)
EC (1) ECSP14033267A (enExample)
ES (1) ES2644812T3 (enExample)
GT (1) GT201400288A (enExample)
HR (1) HRP20171515T1 (enExample)
HU (1) HUE034425T2 (enExample)
IL (1) IL236219A (enExample)
JO (1) JO3296B1 (enExample)
LT (1) LT2867207T (enExample)
MA (1) MA37686B1 (enExample)
ME (1) ME02840B (enExample)
MX (1) MX345324B (enExample)
MY (1) MY173878A (enExample)
NZ (1) NZ701933A (enExample)
PE (1) PE20150182A1 (enExample)
PH (1) PH12015500009B1 (enExample)
PL (1) PL2867207T3 (enExample)
PT (1) PT2867207T (enExample)
RS (1) RS56452B1 (enExample)
SG (1) SG11201408641UA (enExample)
SI (1) SI2867207T1 (enExample)
TN (1) TN2014000501A1 (enExample)
TW (1) TWI599561B (enExample)
UA (1) UA114325C2 (enExample)
WO (1) WO2014004229A1 (enExample)
ZA (1) ZA201408632B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR091429A1 (es) * 2012-06-29 2015-02-04 Lilly Co Eli Compuestos de fenoxietil piperidina
TWI636046B (zh) * 2013-05-17 2018-09-21 美國禮來大藥廠 苯氧基乙基二氫-1h-異喹啉化合物
PL3083562T3 (pl) * 2013-12-17 2018-02-28 Eli Lilly & Company Pochodne fenoksyetylowych cyklicznych amin i ich aktywność jako modulatorów receptora EP4
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
SG11201908660RA (en) 2017-05-18 2019-10-30 Idorsia Pharmaceuticals Ltd N-substituted indole derivatives
PL3625228T3 (pl) 2017-05-18 2021-12-20 Idorsia Pharmaceuticals Ltd Pochodne pirymidyny jako modulatory receptora pge2
IL270623B2 (en) 2017-05-18 2023-03-01 Idorsia Pharmaceuticals Ltd History of phenyl as pge2 receptor modulators
AR111807A1 (es) 2017-05-18 2019-08-21 Idorsia Pharmaceuticals Ltd Derivados de benzofurano y benzotiofeno como moduladores del receptor pge2
JP7253500B2 (ja) 2017-05-18 2023-04-06 イドーシア ファーマシューティカルズ リミテッド ピリミジン誘導体
CA3126484A1 (en) * 2019-01-22 2020-07-30 Keythera (Suzhou) Pharmaceuticals Co. Ltd. Compound for inhibiting pge2/ep4 signaling transduction inhibiting, preparation method therefor, and medical uses thereof
US20230390303A1 (en) 2020-11-13 2023-12-07 Ono Pharmaceutical Co., Ltd. Cancer treatment by combination of ep4 antagonist and immune checkpoint inhibitor
GB202211232D0 (en) 2022-08-02 2022-09-14 Heptares Therapeutics Ltd Prostaglandin EP4 receptor agonist compounds

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2500157C2 (de) 1975-01-03 1983-09-15 Hoechst Ag, 6230 Frankfurt N-Acyl-4-(2-aminoäthyl)-benzoesäuren, deren Salze und Ester, Verfahren zu deren Herstellung und deren Verwendung
JP2005531516A (ja) * 2002-03-18 2005-10-20 ファイザー・プロダクツ・インク 選択的ep4受容体アゴニストによる治療方法
MXPA05007341A (es) * 2003-01-10 2005-09-30 Hoffmann La Roche Derivados de 2-piperidona como agonistas de prostaglandina.
MXPA06002551A (es) * 2003-09-03 2006-06-20 Pfizer Compuestos de aril o heteroaril amida.
US20050105732A1 (en) * 2003-11-17 2005-05-19 Hutchings George T. Systems and methods for delivering pre-encrypted content to a subscriber terminal
EA200601847A1 (ru) 2004-05-04 2007-04-27 Пфайзер Инк. Замещённые метиларил- или гетероариламидные соединения
AP2006003769A0 (en) 2004-05-04 2006-10-31 Pfizer Ortho substituted aryl or heteroaryl amide compounds
US7592364B2 (en) * 2006-02-28 2009-09-22 Allergan, Inc. Substituted gamma lactams as therapeutic agents
US7968578B2 (en) 2006-04-24 2011-06-28 Merck Frosst Canada Ltd. Indole amide derivatives as EP4 receptor antagonists
AU2007260529B2 (en) 2006-06-12 2012-04-19 Merck Canada Inc. Indoline amide derivatives as EP4 receptor ligands
WO2008092860A1 (en) * 2007-01-30 2008-08-07 Janssen Pharmaceutica N.V. Bicyclic derivatives as ep4 agonists
RU2479576C9 (ru) 2008-05-14 2014-03-10 Астеллас Фарма Инк. Амидное соединение
US8404736B2 (en) 2008-08-14 2013-03-26 Beta Pharma Canada Inc. Heterocyclic amide derivatives as EP4 receptor antagonists
KR101780666B1 (ko) * 2010-02-22 2017-09-21 에스크엣 인크. Il-23 매개 질환의 치료에서 ep4 수용체 길항제의 용도
EP2619182B1 (en) * 2010-09-21 2016-11-09 Eisai R&D Management Co., Ltd. Pharmaceutical composition
ES2564353T3 (es) 2011-07-04 2016-03-22 Rottapharm Biotech S.R.L. Derivados de aminas cíclicas como agonistas de los receptores EP4
BR112014000087B1 (pt) * 2011-07-04 2021-08-17 Rottapharm Biotech S.R.L. Derivados de amina cíclica como antagonistas do receptor ep4
AR091429A1 (es) * 2012-06-29 2015-02-04 Lilly Co Eli Compuestos de fenoxietil piperidina

Also Published As

Publication number Publication date
RS56452B1 (sr) 2018-01-31
AR091429A1 (es) 2015-02-04
KR101653476B1 (ko) 2016-09-01
GT201400288A (es) 2015-08-27
EP2867207A1 (en) 2015-05-06
SI2867207T1 (sl) 2017-10-30
US9402838B2 (en) 2016-08-02
PE20150182A1 (es) 2015-02-13
SG11201408641UA (en) 2015-01-29
CA2875569C (en) 2016-04-19
CN104411684A (zh) 2015-03-11
ECSP14033267A (es) 2015-09-30
JO3296B1 (ar) 2018-09-16
US20140005226A1 (en) 2014-01-02
EA024392B1 (ru) 2016-09-30
HK1203937A1 (en) 2015-11-06
TWI599561B (zh) 2017-09-21
BR112014031616A2 (pt) 2017-06-27
MA37686B1 (fr) 2017-04-28
TW201412717A (zh) 2014-04-01
IL236219A (en) 2017-12-31
DK2867207T3 (en) 2017-09-11
HUE034425T2 (en) 2018-02-28
EP2867207B1 (en) 2017-08-09
ZA201408632B (en) 2017-06-28
EA201492255A1 (ru) 2015-03-31
KR20150013893A (ko) 2015-02-05
JP2015522018A (ja) 2015-08-03
PH12015500009B1 (en) 2020-10-09
BR112014031616B1 (pt) 2022-06-21
PL2867207T3 (pl) 2018-01-31
US8962659B2 (en) 2015-02-24
MX2014015953A (es) 2015-07-17
CR20140553A (es) 2015-02-04
AU2013280875A1 (en) 2014-12-04
MX345324B (es) 2017-01-25
IL236219A0 (en) 2015-02-01
MY173878A (en) 2020-02-26
UA114325C2 (uk) 2017-05-25
WO2014004229A1 (en) 2014-01-03
CL2014003535A1 (es) 2015-05-08
LT2867207T (lt) 2017-10-10
NZ701933A (en) 2017-01-27
DOP2014000287A (es) 2015-01-31
PH12015500009A1 (en) 2015-03-02
AU2013280875B2 (en) 2015-09-24
ES2644812T3 (es) 2017-11-30
CA2875569A1 (en) 2014-01-03
CN104411684B (zh) 2016-08-24
US20150126555A1 (en) 2015-05-07
CO7151507A2 (es) 2014-12-29
MA37686A1 (fr) 2016-09-30
TN2014000501A1 (en) 2016-03-30
CY1119425T1 (el) 2018-03-07
PT2867207T (pt) 2017-11-01
AP2014008164A0 (en) 2014-12-31
ME02840B (me) 2018-01-20
JP6127136B2 (ja) 2017-05-10

Similar Documents

Publication Publication Date Title
HRP20171515T1 (hr) Spojevi fenoksietilpiperidina
ME02910B (me) Spojevi tetrahidropirolotiazina
ME02896B (me) Fenoksietilni derivati prstenastog amina i njihova aktivnost kao modulatora receptora ep4
HRP20171648T1 (hr) Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze
HRP20181048T1 (hr) Neuroaktivni 19-alkoksi-17-supstituirani steroidi, korisni u postupcima liječenja
HRP20201949T1 (hr) 7-benzil-4-(4-(trifluorometil)benzil)-1,2,6,7,8,9-heksahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(4h)-on i njegove soli i njihova primjena u terapiji
HRP20150770T1 (hr) Terapijska kombinacija koja sadrži dolutegravir, abakavir i lamivudin
NZ612000A (en) Bicyclo[3.2.1]octyl amide derivatives and uses of same
FI3256218T3 (fi) Kdm1a-estäjät sairauksien hoidossa
HRP20171512T1 (hr) Derivati betulina
HRP20161103T1 (hr) Kemijski spojevi
HRP20161379T1 (hr) Inhibitori hepatitis c virusa
MY174188A (en) Heterocyclyl compounds
HRP20120830T1 (hr) Imidazolkarboksamidi
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
HRP20140011T1 (hr) Derivati oksazina i njihova uporaba u lijeäśenju neuroloških poremeä†aja
ME02576B (me) Derivati tetrahidropirolotiazina kao inhibitori bace
HRP20151000T1 (hr) Antivirusni spojevi
HRP20180237T4 (hr) Metode za liječenje hcv-a
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
MX375925B (es) Compuestos imidazo[1,2-a]pirazin-1-il-benzamida para tratar atrofia muscular espinal.
BR112014005407A2 (pt) composto, composição farmacêutico, uso do composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de um paciente infectado com hcv
BR112015022077A2 (pt) composto de pirazol-amida e usos medicinais do mesmo
EA201491321A1 (ru) Фторметил-5,6-дигидро-4н-[1,3]оксазины
ME02566B (me) Derivati imidazopiridazina kao modulatori receptora gabaa